CANDACE CAMELON: Open Payments
NPI 1316193287 · CARSON CITY, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$456 in 21 payments from 10 companies in 2025. Trend: 2023 $123 · 2024 $191 · 2025 $456
Food & beverage: $456
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 7 | $118 |
| Astellas Pharma US Inc | 4 | $116 |
| PFIZER INC. | 2 | $55 |
| Merck Sharp & Dohme LLC | 2 | $36 |
| Edwards Lifesciences Corporation | 1 | $35 |
| Amgen Inc. | 1 | $27 |
| Abbott Laboratories | 1 | $23 |
| Seqirus USA Inc | 1 | $15 |
| Exact Sciences Corporation | 1 | $15 |
| ABBVIE INC. | 1 | $15 |
Products named: Veozah, Ozempic, NURTEC ODT, SAPIEN 3 Ultra RESILIA, KRYSTEXXA, FREESTYLE LIBRE 3, ROTATEQ, GARDASIL 9.
Industry payments across NV — which companies pay providers there.
